Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
暂无分享,去创建一个
E. van Limbergen | A. Giobbie-Hurder | B. van Calster | P. Neven | R. Paridaens | H. Wildiers | G. Viale | G. Floris | M. Regan | I. Vergote | B. Thürlimann | A. Smeets | C. Weltens | L. Slembrouck | O. Brouckaert | E. Christodoulou | S. Olbrecht | K. Van Asten | L. Jongen | B. Van calster
[1] E. Scarpi,et al. The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial , 2020, Therapeutic advances in medical oncology.
[2] Daniel F. Hayes,et al. 20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.
[3] R. Heidel,et al. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data , 2017, Breast Cancer Research and Treatment.
[4] C. Hudis,et al. Estimating the OncotypeDX score: validation of an inexpensive estimation tool , 2017, Breast Cancer Research and Treatment.
[5] Leslie Cope,et al. Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Bast,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Szabo,et al. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score. , 2016, Hematology/oncology and stem cell therapy.
[8] L. Cope,et al. A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay. , 2015, Clinical breast cancer.
[9] R. Gelber,et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[11] A. Luini,et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.
[12] A. Thompson,et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study , 2013, British Journal of Cancer.
[13] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] D. Dabbs,et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis , 2013, Modern Pathology.
[15] C. Markopoulos. Overview of the use of Oncotype DX® as an additional treatment decision tool in early breast cancer , 2013, Expert review of anticancer therapy.
[16] C. Perou,et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. van Limbergen,et al. Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] E. Mardis,et al. A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen , 2012, Clinical Cancer Research.
[19] J. Cuzick,et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Giobbie-Hurder,et al. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer , 2011, Breast Cancer Research.
[21] B. van Calster,et al. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[23] Adrian V. Lee,et al. Molecular profiles of progesterone receptor loss in human breast tumors , 2009, Breast Cancer Research and Treatment.
[24] E. van Limbergen,et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Wells,et al. Predictive markers in breast cancer – the present , 2007, Histopathology.
[26] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[27] C. Osborne,et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Schemper. Cox Analysis of Survival Data with Non‐Proportional Hazard Functions , 1992 .
[29] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[30] I Persson,et al. The relation between survival and age at diagnosis in breast cancer. , 1986, The New England journal of medicine.
[31] W. McGuire,et al. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] E. Rutgers,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] F. Monzon. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .
[34] S. Romain,et al. Steroid receptor distribution in 47,892 breast cancers. A collaborative study of 7 European laboratories. The EORTC Receptor Study Group. , 1995, European journal of cancer.
[35] C. Rose,et al. Oestrogen and progesterone receptor determinations in breast cancer: technology and biology. , 1986, Cancer surveys.